Drug Profile
Research programme: TBK1/IKKe inhibitors - Domainex
Latest Information Update: 18 Jun 2021
Price :
$50
*
At a glance
- Originator Domainex
- Class Small molecules
- Mechanism of Action I-kappa B kinase inhibitors; TBK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Chronic obstructive pulmonary disease; Inflammation
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (PO)
- 28 May 2018 No recent reports of development identified for research development in Inflammation in United Kingdom (PO)
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in United Kingdom (PO)